Back to search

BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering

Subpopulation heterogeneitY and MicroenvironMental Engagement as predictors for Treatment Resistance in lYmphoma

Alternative title: Subpopulation heterogeneitY and MicroenvironMental Engagement as predictors for Treatment Resistance in lYmphoma

Awarded: NOK 3.1 mill.

Lymphomas, like most other cancers, consist of multiple distinct cancer cell populations within each patient. These tumor subpopulations have distinct genetic and biological characteristics leading to different drug response profiles. The aim of this project is to characterize these tumor subpopulations in aggressive lymphoma on multiple biological levels including gene mutations, gene expression, protein abundance, surface protein profiles, and drug response. Using the in-depth characterization of subpopulations in the discovery cohort we will investigate large clinical patient cohorts with multiparametric immunofluorescence and describe the association of subclonal histology and response to chemotherapy. The improved understanding of tumor subpopulations and their impact on therapy efficacy combined with the ability to detect those subpopulations in diagnostic biopsies using multiparametric immunofluorescence has the potential to improve treatment stratification and thereby patient survival while reducing side-effects and treatment costs. As the Norwegian partner in this EU project, we provide statistical and machine learning expertise within the project. We have been working on the development of a statistical model which will allow us to use the characterisation of the individual cell types through single-cell omics to improve the prognosis of disease progression. Models linking single-cell data with survival information do not yet exist, partially because only very few data sets exist that can be used for this modelling. Within this project we have a uniquely large data set available, which opens up the possibility for developing such models, which in turn will allow us to learn more about how tumor heterogeneity drives lymphoma patient survival. So far, we have finalised the mathematical formulation of the model and the development of the algorithm which will be the basis for the software implementation of the model. Current work focuses on the software development and running simulation studies to study the properties of the model.

While heterogeneity between patients (inter-tumour heterogeneity) is known to affect treatment efficacy, most personalized treatment approaches do not account for intra-tumour heterogeneity (ITH). New single-cell omics assays provide us, for the first time, with the opportunity to molecularly detect and characterise both genetic and non-genetic ITH. We will use viably frozen lymph node biopsies to thoroughly characterize lymphoma subpopulations and their cellular microenvironment. As a starting point we will use CITE-Seq, characterizing the transcriptome and surface proteome of single cells, and single-cell DNA-Seq, revealing ITH at high resolution. Distinct lymphoma subpopulations will be isolated by single-cell-Seq informed flow cytometry followed by genome sequencing, in depth proteomics and ex-vivo drug sensitivity profiling. We will determine the minimal number of features needed to characterize ITH using the multi-omics data of fresh frozen samples. This set of markers will be used to trace ITH in formalin fixed paraffin embedded (FFPE) tissue by multiplexed immunofluorescence, which enables, if successful, the investigation of ITH in clinical routine samples. The transcriptome, genome and proteome of tumour cell subpopulations in FFPE samples will be evaluated by digital spatial profiling (DSP) and laser microcapture microscopy followed by sequencing and proteome analysis. We will use these data generated in this consortium to develop an automated image analysis pipeline, which estimates the degree of ITH in routine clinical samples and which is suitable to risk stratify lymphoma patients. Ideally, we aim to link recurrent treatment resistant subpopulations to resistance mechanisms and clinically exploitable drug sensitivity profiles. Our results will demonstrate how to overcome the limited applicability of state-of-the-art single cell techniques in routine diagnostic biopsies and will foster the development of patient stratification tools for cancer.

Publications from Cristin

No publications found

No publications found

No publications found

No publications found

Funding scheme:

BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering